Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis

References

• Vilsbøll AW, Anderson P, Piercy J, et al. Extent and impact of inadequate disease control in US adults with a history of moderate to severe atopic dermatitis following introduction of new treatments. Dermatol Ther. 2021;11(2):1–8. doi: 10.1007/s13555-021-00488-x.
   Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347. doi: 10.1016/j.anai.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Rerknimitr P, Otsuka A, Nakashima C, et al. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14.
   PubMed Web of Science ®Google Scholar
• Honda T, Kabashima K. Reconciling innate and acquired immunity in atopic dermatitis. J Allergy Clin Immunol. 2020; Apr145(4):1136–1137. doi: 10.1016/j.jaci.2020.02.008.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–1055. doi: 10.1001/jamadermatol.2021.3023.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884. doi: 10.1016/j.jaci.2019.11.025.
   PubMed Web of Science ®Google Scholar
• Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/S0140-6736(21)00589-4.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343. doi: 10.1001/jamadermatol.2020.3260.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE Mono-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266. doi: 10.1016/S0140-6736(20)30732-7.
   PubMed Web of Science ®Google Scholar
• Ständer S, Kwatra SG, Silverberg JI, et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: subgroup analysis of the randomized phase III JADE COMPARE trial. Am J Clin Dermatol. 2023;24(1):97–107. doi: 10.1007/s40257-022-00738-4.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158–1167. doi: 10.1111/1346-8138.16549.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The eosinophil-to-Lymphocyte ratio acts as an indicator for improvement of clinical signs and itch by upadacitinib treatment in atopic dermatitis. J Clin Med. 2023;12(6):2201. doi: 10.3390/jcm12062201.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023;34(1):2212095.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869–879. doi: 10.1111/1346-8138.16763.
   PubMed Web of Science ®Google Scholar
• Hagino TY, Hamada R, Fujimoto E, et al. Therapeutic effectiveness of upadacitinib on individual types of rash in japanese patients with moderate-to-severe atopic dermatitis. J Dermatol. 2023;2023:16950. doi: 10.1111/1346-8138.16950.
   Google Scholar
• Kosaka K, Uchiyama A, Ishikawa M, et al. Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study. Eur J Dermatol. 2022;32(6):800–802. doi: 10.1684/ejd.2022.4365.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Ortoncelli M, Schena D, et al. Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation. Am J Clin Dermatol. 2023;24(6):953–961. doi: 10.1007/s40257-023-00798-0.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Piscazzi F, et al. Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: a 52-week retrospective study. J Eur Acad Dermatol Venereol. 2023;2023:19507. doi: 10.1111/jdv.19507.
   Google Scholar
• Kiefer S, König A, Gerger V, et al. Efficacy and treatment satisfaction of different systemic therapies in children and adolescents with moderate-to-severe atopic dermatitis: a real-world study. J Clin Med. 2023;12(3):820.
   PubMed Web of Science ®Google Scholar
• Licata G, Tancredi V, Calabrese G, et al. Atopic dermatitis and difficult-to-treat areas: a case series of four patients with dupilumab-resistant primary atopic blepharitis and successfully treated with upadacitinib. Dermatitis. 2023. doi: 10.1089/derm.2023.0196.
   Google Scholar
• Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448–458. doi: 10.1016/j.alit.2022.06.009.
   PubMed Web of Science ®Google Scholar
• Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36(3):367–376. doi: 10.1080/03007995.2019.1699516.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2.
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Ganchingco JR, Mishra SK, et al. Janus kinase inhibitors display broad anti-itch properties: a possible link through the TRPV1 receptor. J Allergy Clin Immunol. 2017;140(1):306–309.e3. doi: 10.1016/j.jaci.2016.12.960.
   PubMed Web of Science ®Google Scholar
• Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis. Exp Dermatol. 2018;27(4):327–331. doi: 10.1111/exd.13533.
   PubMed Web of Science ®Google Scholar
• Toussirot E. The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition. Metabolites. 2020; Mar 1310(3):107. doi: 10.3390/metabo10030107.
   PubMed Web of Science ®Google Scholar
• Roskoski R.Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187:106552. doi: 10.1016/j.phrs.2022.106552.
   PubMed Web of Science ®Google Scholar
• Popko K, Gorska E, Stelmaszczyk-Emmel A, et al. Proinflammatory cytokines Il-6 and TNF-α and the development of inflammation in obese subjects. Eur J Med Res. 2010;15(Suppl 2):120–122. doi: 10.1186/2047-783x-15-s2-120.
   PubMedGoogle Scholar
• Giles JT, Ogdie A, Gomez Reino JJ, et al. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. RMD Open. 2021;7(1):e001486. doi: 10.1136/rmdopen-2020-001486.
   PubMed Web of Science ®Google Scholar
• Cristiano AF, Zerbini DM, Arora VK, et al. Effect of BMI on baricitinib efficacy: pooled analysis from two phase 3 rheumatoid arthritis clinical trials. Arthritis Rheumatol. 2016;68:1640.
   Google Scholar